Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses film aims to stop nearsightedness before it starts

NCT ID NCT07401511

Prevention Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special optical film called S.T.O.P®KIT that attaches to eyeglasses. The goal is to slow down the growth of the eye in children aged 6 to 10 with mild farsightedness, which may help prevent nearsightedness later. 180 children will be split into two groups: one gets the special glasses, the other gets regular check-ups. The study will measure changes in eye length and vision over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dynamic Spatiotemporal Optical Film (S.T.O.P®KIT) attached to eyeglasses
What this could lead to
If it works, this could provide a simple, non-invasive way to prevent nearsightedness in children with mild farsightedness.
What could go wrong
This is an early-stage study with only 180 children, and it's not yet recruiting. The effect may be small or not work at all, and results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 10 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible study participants must meet all the following criteria: 1. Age: 6-10 years old; * +0.75D ≤ Spherical equivalent power ≤ +3.00D; * Anisometropia ≤ 1.50D; * Astigmatism ≤ 1.50D; * No participation in other myopia prevention and control studies or use of other myopia prevention and control methods (including low-concentration atropine eye drops, defocus eyeglasses, orthokeratology lenses, multifocal soft contact lenses, etc.) within 3 months; * Best-corrected visual acuity (BCVA) in both eyes ≥ 0.8 using a standard logarithmic visual acuity chart; * Ability to wear frame glasses during near work for at least 6 hours per day; * Study participants or their legal representatives sign the informed consent form. Exclusion Criteria: * Patients with strabismus; * Patients with abnormal stereopsis; * Comorbidity with other ophthalmic diseases, including developmental abnormalities affecting visual function and refractive status; * Previous ocular surgery history; * Previous receipt of other myopia control treatments (including orthokeratology lenses, multifocal design soft contact lenses or frame glasses, drug therapy \[atropine\], visual training, etc.); * Current use of medications that may affect pupil size and ocular surface function; * Comorbidity with other systemic diseases that may affect visual function or refractive status; * Family history of hereditary ophthalmic diseases; * Other conditions deemed unsuitable for participation by investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Children are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Children Hyperopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200080, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhenzhou, Henan, 450052, China

  • Yuhuangding Hospital of Yantai

    Yantai, Shandong, 264000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.